Failure of STEP leads TAG to criticise the proposed PAVE100A vaccine trial

HIV Treat Bull - 2008 July-August;9(7/8):

The failure of STEP trial, using Merck’s adenovirus serotype 5 (Ad5)-based HIV vaccine, has implications for using another Ad5 candidate in the proposed PAVE100A Phase IIb efficacy trial.

The STEP trial neither reduced infection or post-infection viral load, and potentially increased infection rates among a subset of trial participants.

Treatment Action Group (TAG), a influential community-based policy think-tank published a Position Statement that raises serious concerns about continuing with the PAVE100A trial.

This includes an analysis of the scientific likely hood that this new candidate will produce a different response, and questioning both the relevance and safety of such a restricted study population:the PAVE trial is limiting recruitment to circumcised gay men with no detectable antibody responses to Ad5.

TAG proposes abandoning plans for this particular clinical trial and Ad5 vaccine candidate in favour of supporting research to rapidly address two key issues:

1. The use of an alternate vector or DNA approach for the boosting immunisation that could be studied in a broader population.
2. Inducing broader responses to proteins contained in the vaccine, particularly HIV-1 Gag.

They argue against spending human and fiscal resources on PAVE100A, and instead suggest focusing on improving T cell-based immunogens so they can be studied in a broader population with a greater chance of success.

Source:
TAG Basic Science Blog (30 May 2008)

The full statement “TAG position statement on the proposed PAVE100A vaccine trial” is available online

2008-07-10
IB080907-23

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.